ArticleThoracic cancer2019
Lung cancer outcome in the setting of chronic kidney disease: Does the glomerular filtration estimation formula matter?
Article in Thoracic cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Decreased Preoperative Estimated Glomerular Filtration Rate Was Related With Poor Prognosis of NSCLC Patients.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe survival outcomes of lung cancer patients with coexisting chronic kidney disease (CKD) reported in the literature have been conflicting. We evaluate whether the survival of lung cancer patients with and without CKD differ significantly using two different formulas.
methodsA retrospective, multicenter, propensity-matched study of lung cancer patients with and without CKD was conducted. CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 mL/minute. Kaplan-Meier survival analysis was used to determine survival differences between CKD and non-CKD patients using the Cockcroft-Gault formula (CKD-CG) compared to the Chronic Kidney Disease Epidemiology Collaboration Formula (CKD-EPI).
resultsBaseline clinical characteristics did not differ statistically significantly between the groups. The CKD-CG formula demonstrated median survival of 10.61 months (95% confidence interval [CI] 9.33-11.89) for the non-CKD group compared to 10.58 months (95% CI 9.03-12.13) for the CKD group (P = 0.76). The CKD-EPI formula demonstrated median survival of 9.10 months (95% CI 8.01-10.20) for the non-CKD group compared to 7.59 months (95% CI 6.50-8.68) for the CKD group (P = 0.19). Cox regression analysis using both models revealed that CKD is not an independent risk factor for mortality in lung cancer patients. Although the CKD-EPI formula revealed an increased risk of mortality and the CKD-CG formula revealed decreased survival, these results were not statistically significant.
conclusionLung cancer survival did not differ significantly between CKD and non-CKD patients using either formula.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.